Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The sto ...

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA ...

Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan By Angus Liu Apr 23, 2025 10:35am Bristol Myers Squibb Cobenfy schizophrenia atypical ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that would help expand its use, sending its shares ...

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ambitions to turn it into a blockbuster.

Cobenfy (xanomeline/trospium chloride) is a prescription oral capsule that treats schizophrenia in adults. Learn about dosage, side effects, and more.

Cognitive issues are core symptoms of schizophrenia. More than 80 percent of people with schizophrenia have cognitive symptoms of some kind. They’re one of the main obstacles to managing schizophrenia ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.